RAP-219 Shows Sustained Seizure Reduction, Improved Half-Life in Phase 2a Follow-up for Focal Onset Seizures
Summary
Rapport Therapeutics announced positive follow-up results from its Phase 2a trial of RAP-219 for focal onset seizures, demonstrating sustained seizure reduction and an improved half-life. The data, presented at the American Academy of Neurology Annual Meeting, showed a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in weeks 13-16, following the 8-week treatment period. Additionally, RAP-219's estimated half-life increased to approximately 22 days from a prior 14-day estimate, suggesting prolonged therapeutic levels. The drug was also generally well tolerated. These sustained efficacy and improved pharmacokinetic properties are highly positive for the drug's development and potential market positioning, building on the previously reported positive Phase 2a data mentioned in the company's recent 10-K. This strengthens the investment thesis for RAPP's lead candidate and de-risks future clinical progression. Investors will now watch for further updates on Phase 3 trial initiation and regulatory interactions.
At the time of this announcement, RAPP was trading at $36.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $7.73 to $42.27. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.